Skip to main navigation

Overview
New & Events
- Press Releases
- Events & Presentations
Stock Information
Financial Information
- SEC Filings
Corporate Governance
Investor Resources

Press Releases

Press Releases

Year

Jan 04, 2021

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

Print Page

RSS Feeds

Email Alerts

Investor Contact

Investor Contact

© 2021 Pandion Therapeutics. All rights reserved.